



(12) Translation of
European patent specification

(11) NO/EP 2758388 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/04 (2006.01)
A61K 31/4709 (2006.01)
A61P 9/12 (2006.01)
C07D 471/04 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2018.07.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.02.21
(86)	European Application Nr.	12766628.7
(86)	European Filing Date	2012.09.20
(87)	The European Application's Publication Date	2014.07.30
(30)	Priority	2011.09.23, WO, PCT/CN11/080078
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, CH-Sveits
(72)	Inventor	AEBI, Johannes, Im Kugelfang 27, 4102 Binningen, CH-Sveits AMREIN, Kurt, Lettenweg 8, 4452 Ittingen, CH-Sveits FANTASIA, Serena, Maria, Hochstrasse 80, 4053 Basel, CH-Sveits HORNSPERGER, Benoit, 9, rue des Sources, 68130 Altkirch, FR-Frankrike KUHN, Bernd, Hinterlindenweg 26a, 4153 Reinach BL, CH-Sveits LIU, Yongfu, Roomk 303, No. 5, Lane 652Kongjiang RoadYangpu District, Shanghai 200093, CN-Kina MAERKI, Hans P., Seltisbergerstrasse 75, 4059 Basel, CH-Sveits MAYWEG, Alexander, V., Martinsgasse 8, 4051 Basel, CH-Sveits Mohr, Peter, Benkenstrasse 26, 4054 Basel, CH-Sveits SCALONE, Michelangelo, Baslerstrasse 14, 4127 Birsfelden, CH-Sveits TAN, Xuefei, Room 101, No. 20, Lane 300Jinxu Road, Pudong, Shanghai 200135, CN-Kina ZHOU, Mingwei, Roomk 1505, Lane 3046Chuan Bei Road, Shanghai 101210, CN- Kina
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54)	Title	NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES
(56)	References Cited:	WO-A1-2009/135651

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelser med formel (I)



hvor

- 5 R^1 er C_1 - C_7 -alkyl;
 R^2 er H;
 R^3 er H;
 R^4 er H;
 R^5 er H;
- 10 R^6 er H, halogen eller C_1 - C_7 -alkyl;
 R^7 er H;
 R^8 er H;
 R^9 er H;
 R^{10} er H;
- 15 R^{11} er H;
 R^{12} er H eller halogen;
 A^1 er CR^{13} ;
 A^2 er NR^{14} eller $CR^{15}R^{16}$;
 A^3 er CR^{17} ;
- 20 R^{13} er H eller halogen;
 R^{14} er $-(CR^{20}R^{21})_q-(CR^{22}R^{23})_r-(CR^{24}R^{25})_p-NR^{26}R^{27}$, hvori summen av q, r og p er minst 2;
 R^{15} er $-(CR^{20}R^{21})_q-(CR^{22}R^{23})_r-(CR^{24}R^{25})_p-NR^{26}R^{27}$;
 R^{16} er H;
- 25 eller R^6 og R^{16} sammen med karbonatomene de er festet til, danner en dobbeltbinding;

- R^{17} er H;
 R^{20} er H;
 R^{21} er H;
 R^{22} er H;
5 R^{23} er H;
 R^{24} er H;
 R^{25} er H;
 R^{26} er H;
 R^{27} er H, $-S(O)_2R^{31}$, $-C(O)R^{31}$ eller $-C(O)OR^{31}$, hvori dersom R^{26} er H og R^{27} er H, er
10 summen av q, r og p minst 1;
 R^{31} er C_1 - C_7 -alkyl, hydroksyl- C_1 - C_7 -alkyl, C_3 - C_8 -sykloalkyl eller klorpyridinyl;
n er null eller 1;
p er null eller 1;
q er null eller 1;
15 r er null eller 1;
eller farmasøytisk akseptable salter eller estere.

2. Forbindelse ifølge krav 1, hvori R^6 er H.

- 20 3. Forbindelse ifølge et hvilket som helst av kravene 1 til 2, hvori R^{12} er H.

4. Forbindelse ifølge et hvilket som helst av kravene 1 til 3, hvori A^2 er $CR^{15}R^{16}$.

5. Forbindelse ifølge et hvilket som helst av kravene 1 til 4, hvori R^{27} er $-C(O)R^{31}$.

25

6. Forbindelse ifølge et hvilket som helst av kravene 1 til 5, hvori R^{31} er C_1 - C_7 -alkyl.

7. Forbindelse ifølge et hvilket som helst av kravene 1 til 6, hvori n er 1.

- 30 8. Forbindelse ifølge et hvilket som helst av kravene 1 til 7, hvori q, r og p er null.

9. Forbindelse ifølge et hvilket som helst av kravene 1 til 8, valgt blant

- (ras)-N-[4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (-)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid;
- 5 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid;
- (R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid;
- (S)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-
10 tetrahydroisokinolin-8-yl)propionamid;
- (ras)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)etansulfonamid;
- (-)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)etansulfonamid;
- 15 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)etansulfonamid;
- (R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)etansulfonamid;
- (S)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-
20 tetrahydroisokinolin-8-yl)etansulfonamid;
- (ras)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
- (-)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
- 25 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
- (R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
- (S)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-
30 syklopenta[c]pyridin-7-yl)propionamid;
- (ras)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)etansulfonamid;

{2-[5-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-3,4-dihydro-2H-[1,7]naftyridin-1-yl]-etyl}-karbaminsyre-tert-butylester;
 6-[1-(2-amino-etyl)-1,2,3,4-tetrahydro-[1,7]naftyridin-5-yl]-1-metyl-3,4-dihydro-1H-kinolin-2-on-hydroklorid;
 5 N-{2-[5-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-3,4-dihydro-2H-[1,7]naftyridin-1-yl]-etyl}-propionamid;
 N-(2-(5-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-3,4-dihydro-1,7-naftyridin-1(2H)-yl)etyl)etansulfonamid;
 og farmasøytisk akseptable salter derav.

10

10. Forbindelse ifølge et hvilket som helst av kravene 1 til 8, valgt blant
 (2R,S)-2-hydroksy-N-((4R,S)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 (2R)-2-hydroksy-N-((4R,S)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-
 15 5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 (2S)-2-hydroksy-N-((4R,S)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 (+)-(2R)-2-hydroksy-N-((4R eller 4S)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 20 (-)-(2R)-2-hydroksy-N-((4S eller 4R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 (-)-(2S)-2-hydroksy-N-((4S eller 4R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 (+)-(2S)-2-hydroksy-N-((4R eller 4S)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propanamid;
 25 (ras)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (-)-(S eller R)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 30 (+)-(R eller S)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (ras)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-

- 5H-syklopenta[c]pyridin-7-yl)etansulfonamid;
 (-)-(S eller R)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)etansulfonamid;
 (+)-(R eller S)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)etansulfonamid;
 5 (ras)-N-[4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (-)-(S eller R)-N-[4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 10 (+)-(R eller S)-N-[4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (-)-(S eller R)-etansulfonsyre [4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 (+)-(R eller S)-etansulfonsyre [4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 15 (ras)-N-[4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (ras)-etansulfonsyre [4-(7-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 20 N-[(R eller S)-4-(7-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (ras)-etansulfonsyre [4-(8-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 (ras)-etansulfonsyre [4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 25 (+)-etansulfonsyre [(R eller S)-4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 (-)-etansulfonsyre [(S eller R)-4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 30 (-)-N-[(S eller R)-4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (+)-N-[(R eller S)-4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-

- 5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7S,8R eller 7R,8S)-7-metyl-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (-)-N-[(7S,8S eller 7R,8R)-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-7-metyl-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 5 (-)-N-[(7R,8S eller 7S,8R)-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-7-metyl-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7S,8R eller 7R,8S)-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-7-metyl-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 10 (-)-N-[(7S,8S eller 7R,8R)-7-metyl-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (-)-N-[(7R,8S eller 7S,8R)-7-metyl-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7R,8R eller 7S,8S)-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-7-metyl-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 15 (+)-N-[(7R,8R eller 7S,8S)-7-metyl-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (-)-N-[(7R,8R eller 7S,8S)-7-fluor-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 20 (-)-N-[(7S,8R eller 7R,8S)-7-fluor-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7S,8S eller 7R,8R)-7-fluor-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7R,8S eller 7S,8R)-7-fluor-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 25 (+)-N-[(7S,8S eller 7R,8R)-7-fluor-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (+)-N-[(7R,8S eller 7S,8R)-7-fluor-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- 30 (-)-N-[(7R,8R eller 7S,8S)-7-fluor-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
- (-)-N-[(7S,8R eller 7R,8S)-7-fluor-4-(7-fluor-1-metyl-2-okso-1,2,3,4-

- tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (ras)-N-(4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (-)-(S eller R)-N-(4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-
 5 dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (+)-(R eller S)-N-(4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (R)-6-(8-amino-5,6,7,8-tetrahydroisokinolin-4-yl)-1-metyl-3,4-dihydrokinolin-2(1H)-on;
 10 3-klor-pyridin-2-karboksytsyre[(R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 N-[(R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-acetamid;
 Syklopropankarboksytsyre [(R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 15 N-[(R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-metansulfonamid;
 Syklopropansulfonsyre [(R)-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-amid;
 20 (ras)-6-(8-hydroksy-5,6,7,8-tetrahydroisokinolin-4-yl)-1-metyl-3,4-dihydrokinolin-2(1H)-on;
 (S eller R)-6-(8-hydroksy-5,6,7,8-tetrahydroisokinolin-4-yl)-1-metyl-3,4-dihydrokinolin-2(1H)-on;
 (R eller S)-6-(8-hydroksy-5,6,7,8-tetrahydroisokinolin-4-yl)-1-metyl-3,4-
 25 dihydrokinolin-2(1H)-on;
 1-metyl-6-(8-okso-5,6,7,8-tetrahydroisokinolin-4-yl)-3,4-dihydro-1H-kinolin-2-on;
 N-[4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6-dihydroisokinolin-8-yl]-propionamid;
 30 (+)-(R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid;
 og farmasøytisk akseptable salter derav.

11. Forbindelse ifølge et hvilket som helst av kravene 1 til 9, valgt blant
 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-
 tetrahydroisokinolin-8-yl)propionamid;
- 5 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-
 tetrahydroisokinolin-8-yl)etansulfonamid;
 (+)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-
 syklopenta[c]pyridin-7-yl)propionamid;
 (ras)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-dihydro-5H-
 10 syklopenta[c]pyridin-7-yl)etansulfonamid;
 N-{2-[5-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-3,4-dihydro-2H-
 [1,7]naftyridin-1-yl]-etyl}-propionamid;
 og farmasøytisk akseptable salter derav.
- 15 12. Forbindelse ifølge et hvilket som helst av kravene 1 til 8 og 10, valgt blant
 (+)-(R eller S)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-
 dihydro-5H-syklopenta[c]pyridin-7-yl)propionamid;
 (+)-(R eller S)-N-(4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-6,7-
 dihydro-5H-syklopenta[c]pyridin-7-yl)etansulfonamid;
- 20 (+)-(R eller S)-N-[4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-
 5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (+)-N-[(R eller S)-4-(8-klor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-
 5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (+)-N-[(7S,8R eller 7R,8S)-7-metyl-4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-
 25 6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 (+)-N-[(7R,8R eller 7S,8S)-4-(7-fluor-1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-
 6-yl)-7-metyl-5,6,7,8-tetrahydroisokinolin-8-yl]-propionamid;
 og farmasøytisk akseptable salter derav.
- 30 13. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, hvori forbindelsen
 er (+)-(S eller R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-
 tetrahydroisokinolin-8-yl)propionamid eller farmasøytisk akseptable salter derav.

14. Forbindelse ifølge et hvilket som helst av kravene 1 til 8, 10 og 12, hvori forbindelsen er (+)-(R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid eller farmasøytisk akseptable salter derav.

15. Forbindelse ifølge et hvilket som helst av kravene 1 til 14 for anvendelse som et terapeutisk aktivt stoff.

16. Forbindelse for anvendelse ifølge krav 15, hvori forbindelsen er (+)-(R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid eller farmasøytisk akseptable salter derav.

17. Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 14 og en terapeutisk inert bærer.

18. Farmasøytisk sammensetning ifølge krav 17, hvori forbindelsen er (+)-(R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid eller farmasøytisk akseptable salter derav.

19. Forbindelse ifølge et hvilket som helst av kravene 1 til 14 for anvendelse ved behandling eller profylakse av kronisk nyresykdom, kongestiv hjertesvikt, hypertensjon, primær aldosteronisme og Cushings syndrom.

20. Forbindelse for anvendelse ifølge krav 19, hvori forbindelsen er (+)-(R)-N-(4-(1-metyl-2-okso-1,2,3,4-tetrahydrokinolin-6-yl)-5,6,7,8-tetrahydroisokinolin-8-yl)propionamid eller farmasøytisk akseptable salter derav.